Comparison of Biosimilar and Innovator Monoclonal Antibody Rituximab Using the Agilent 1260 Infinity Bio-inert LC System and Agilent OpenLAB Match Compare Software

Significance of the Topic

The development of biosimilar monoclonal antibodies requires rigorous analytical demonstration of molecular similarity to the innovator product. Reliable, high-resolution liquid chromatography and objective data comparison help satisfy regulatory requirements, ensure consistent product quality, and support cost-effective biotherapeutic production.

Study Objectives and Overview

This study evaluates the physicochemical and biological comparability between a biosimilar and innovator rituximab. Three orthogonal LC-UV techniques (intact and reduced reverse-phase HPLC, size-exclusion chromatography, and peptide mapping) were applied, alongside a complement-dependent cytotoxicity assay. Agilent’s 1260 Infinity Bio-inert LC system and OpenLAB CDS Match Compare Software were used to streamline analysis and objectively match chromatographic fingerprints.

Methodology and Instrumentation

Samples of both rituximab products were analyzed in three modes:

• Intact protein profiling by RP-HPLC on a Poroshell 120 SB-C18 column.
• Reduced heavy- and light-chain separation by RP-HPLC after DTT treatment.
• Aggregation and purity assessment by SEC using a Bio SEC-3 column under non-reducing and reducing conditions.
• Primary structure confirmation by tryptic peptide mapping on an AdvanceBio Peptide mapping column.

A comparative CDC bioassay measured functional Fc-effector activity on WIL2S cells.

Used Instrumentation

• Agilent 1260 Infinity Bio-inert Quaternary LC Pump (G5611A)
• Agilent 1260 Infinity Bio-inert High Performance Autosampler (G5667A)
• Agilent 1260 Infinity Thermostatted Column Compartment with bio-inert heating (G1316C option 19)
• Agilent 1260 Infinity DAD VL with bio-inert flow cell (G1315D option 28)
• Agilent AdvanceBio Peptide mapping column, Agilent Poroshell 120 SB-C18, Agilent Bio SEC-3 columns
• Agilent OpenLAB CDS ChemStation Edition (Rev. C.01.02), OpenLAB CDS Match Compare (A.01.01.1)

Key Results and Discussion

• Intact RP-HPLC profiles of biosimilar and innovator rituximab showed identical peak patterns and areas, with complete peak matching via software.
• Reduced RP-HPLC separated heavy and light chains within 8 minutes, confirming similar subunit composition despite small retention shifts.
• SEC under non-reducing conditions yielded monomer purity of 99.5 % (innovator) and > 99.25 % (biosimilar); reduced SEC revealed matching heavy- and light-chain peaks.
• Peptide mapping produced superimposable chromatograms with 100 % peak identity across randomly selected peptides.
• CDC assays demonstrated comparable biological activity, with the biosimilar showing 111 % relative potency versus the innovator.

Benefits and Practical Applications

• Objective chromatogram matching reduces manual review errors and accelerates QC workflows.
• High-resolution separations enable rapid assessment of structural variants, aggregates, and post-translational modifications.
• Integrated software tools support regulatory comparability studies and batch-to-batch consistency monitoring.

Future Trends and Opportunities

Advancements in multi-attribute methods, mass spectrometry integration, and AI-driven data analysis promise deeper insight into biosimilar comparability. Automated, cloud-based platforms and real-time quality monitoring will further streamline biopharmaceutical development and ensure enhanced product safety.

Conclusion

The combined LC-UV approach using Agilent 1260 Infinity Bio-inert technology and OpenLAB CDS Match Compare Software provides a robust, objective, and efficient workflow for physicochemical and functional comparability of biosimilar and innovator rituximab. This strategy meets stringent regulatory expectations and supports reliable biosimilar development.

References

• 1. Jan Visser et al. Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab. BioDrugs 2013, 27, pp 495–507.
• 2. Diteba. Protein Characterization. http://www.diteba.com/ProteinCharacterization
• 3. QA/QC of Monoclonal Antibodies: High-resolution peptide mapping analysis using Agilent’s 1260 Infinity Bio-inert Quaternary LC and 1290 Infinity LC Systems. Agilent Technologies Application Note 5991-1694EN.
• 4. OpenLAB CDS Match Compare for Chromatographic Peak Matching and Comparison. Agilent Technologies Data Sheet 5991-2553EN.